The Melanoma market was impacted by adjuvant, advanced / metastatic and brain mets data presented during the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

Breaking Data worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for YERVOY® (ipilimumab), OPDIVO® (nivolumab), TAFINLAR® (dabrafenib) + MEKINIST® (trametinib), BRAFTOVI® (encorafenib) + MEKTOVI® (encorafenib), ZELBORAF® (vemurafenib), spartalizumab, and SD-101.

Companies presenting data included: Bristol-Myers Squibb, Dynavax, Genentech, Merck, Array/Pfizer, Novartis.

Get immediate access to this 63-slide report so you can make better decisions today and prepare for tomorrow.

Melanoma Report ASCO 2019

American Society of Clinical Oncology

Chicago, IL
May 31 to Jun 4

Share: